In Surprising Move, PTAB Tackles Tribal Immunity Head-On

Law360 (February 26, 2018, 10:37 PM EST) -- Deciding it could review the validity of patents covering Allergan PLC’s Restasis drug, the Patent Trial and Appeal Board tackled the issue of tribal sovereign immunity head-on, surprising legal experts who said there were easier ways the board could have resolved the dispute.

The board on Friday denied a motion from the Saint Regis Mohawk Tribe seeking to terminate challenges that Mylan Inc. and other generics companies brought against several Restasis patents. Allergan transferred the patents to the tribe last year, believing the tribe’s status as...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.